Risultati della ricerca - Myung‐Ju Ahn

Raffina i risultati
  1. 1
    Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherapy

    Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherap... di Jong‐Mu Sun, Joungho Han, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn

    Pubblicazione 2011
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  2. 2
    Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes

    Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes di Thomas John, Aliki Taylor, Huifen Wang, Christian Eichinger, Caroline Freeman, Myung‐Ju Ahn

    Pubblicazione 2021
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  3. 3
    Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer

    Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer di Jong‐Mu Sun, Deok Won Hwang, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park

    Pubblicazione 2013
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  4. 4
    Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations

    Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations di Antonio Passaro, Tony Mok, Solange Peters, Sanjay Popat, Myung‐Ju Ahn, Filippo de Marinis

    Pubblicazione 2020
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  5. 5
    Non-small Cell Lung Cancer with Concomitant <i>EGFR</i>, <i>KRAS</i>, and <i>ALK</i> Mutation: Clinicopathologic Features of 12 Cases

    Non-small Cell Lung Cancer with Concomitant <i>EGFR</i>, <i>KRAS</i>, and <i>ALK</i> Mutation: Clinicopathologic Features of 12 Cases di Taebum Lee, Boram Lee, Yoon‐La Choi, Joungho Han, Myung‐Ju Ahn, Sang‐Won Um

    Pubblicazione 2016
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  6. 6
    Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib

    Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib di Youjin Kim, Se‐Hoon Lee, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park, Jong‐Mu Sun

    Pubblicazione 2018
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  7. 7
    Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non–Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either Exon 19 or 21

    Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non–Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either... di Sung Hee Lim, Ji Yun Lee, Jong‐Mu Sun, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn

    Pubblicazione 2014
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  8. 8
    Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non–Small Cell Lung Cancer

    Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non–Small Cell Lung Cancer di Song Ee Park, Se‐Hoon Lee, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park, Jong‐Mu Sun

    Pubblicazione 2017
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  9. 9
    Clues to Occult Cancer in Patients with Ischemic Stroke

    Clues to Occult Cancer in Patients with Ischemic Stroke di Suk Jae Kim, Jae Hyun Park, Mi Ji Lee, Yun Gyoung Park, Myung‐Ju Ahn, Oh Young Bang

    Pubblicazione 2012
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  10. 10
    Cancer-Related Stroke: An Emerging Subtype of Ischemic Stroke with Unique Pathomechanisms

    Cancer-Related Stroke: An Emerging Subtype of Ischemic Stroke with Unique Pathomechanisms di Oh Young Bang, Jong‐Won Chung, Mi Ji Lee, Woo‐Keun Seo, Gyeong‐Moon Kim, Myung‐Ju Ahn

    Pubblicazione 2020
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  11. 11
    Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis

    Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis di Seonggyu Byeon, Jun Soo Ham, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn

    Pubblicazione 2016
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  12. 12
    KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing

    KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing di Tony Kiat Hon Lim, Ferdinandos Skoulidis, Keith M. Kerr, Myung‐Ju Ahn, Joshua Kapp, Fernando Augusto Soares, Yasushi Yatabe

    Pubblicazione 2023
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  13. 13
    A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient with IHC-Positive and FISH-Negative ALK

    A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient with IHC-Positive and FISH-Negative ALK di Jong‐Mu Sun, Yoon‐La Choi, Jae‐Kyung Won, Fred R. Hirsch, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park

    Pubblicazione 2012
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  14. 14
    Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial

    Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial di Myung‐Ju Ahn, Byoung Chul Cho, Xiaoling Ou, Andrew Walding, Angela W. Dymond, Song Ren, Mireille Cantarini, Pasi A. Jänne

    Pubblicazione 2022
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  15. 15
    Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma di Hana Kim, Sehhoon Park, Hyun Ae Jung, Se‐Hoon Lee, Keunchil Park, Yong Chan Ahn, Dongryul Oh, Myung‐Ju Ahn

    Pubblicazione 2023
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  16. 16
    Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non–Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial

    Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non–Small-Cell Lung Cancer: A Biomarker-Stratified Randomize... di Jong‐Mu Sun, Jin Seok Ahn, Sin‐Ho Jung, Jiyu Sun, Sang Yun Ha, Joungho Han, Keunchil Park, Myung‐Ju Ahn

    Pubblicazione 2015
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  17. 17
    Circulating DNAs, a Marker of Neutrophil Extracellular Traposis and Cancer-Related Stroke

    Circulating DNAs, a Marker of Neutrophil Extracellular Traposis and Cancer-Related Stroke di Oh Young Bang, Jong‐Won Chung, Yeon Hee Cho, Mi Jeong Oh, Woo‐Keun Seo, Gyeong‐Moon Kim, Myung‐Ju Ahn

    Pubblicazione 2019
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  18. 18
    An increase of CD8+ T cell infiltration following recurrence is a good prognosticator in HNSCC

    An increase of CD8+ T cell infiltration following recurrence is a good prognosticator in HNSCC di Yoon Kyoung So, Sun‐ju Byeon, Bo Mi Ku, Young Hyeh Ko, Myung‐Ju Ahn, Young‐Ik Son, Man Ki Chung

    Pubblicazione 2020
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  19. 19
    Updated Results of a Global Phase II Study with Crizotinib in Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC)

    Updated Results of a Global Phase II Study with Crizotinib in Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC) di D. Kim, Myung‐Ju Ahn, Pan‐Chyr Yang, X. Liu, Tommaso De Pas, Lucio Crinò, Silvana Lanzalone, Anna Polli, Alice T. Shaw

    Pubblicazione 2012
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  20. 20
    The<i>EGFR</i>T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor

    The<i>EGFR</i>T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor di Young-Wook Kim, Jeong‐Hun Ko, Zheng-Yun Cui, Amir Abolhoda, Jin Seok Ahn, Sai-Hong Ou, Myung‐Ju Ahn, Keunchil Park

    Pubblicazione 2012
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:

Strumenti per la ricerca: